Condition: Colorectal Cancer Liver Metastases · Regorafenib · Sponsor: Sun Yat-sen University
This study is a multicentre, prospective, randomised trial, aims to evaluate the efficacy and safety of Irinotecan Drug-Eluting Beads combined with regorafenib as the third-line treatment for a patient with colorectal cancer liver metastases. The study is planned to enrolled 126 patients failing first- and second-line standard chemotherapy treatment.
This description comes directly from the study's public registry record.
Bo Zhang, M.D · 86-13660397903 · zhangb28@mail.sysu.edu.cn
Bo Zhang, M.D
Always discuss trial participation with your own doctor first.
| Bo Zhang | Guangdong, Guangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05794971